Daniel serves as Managing Partner of Pathway Bioventures, an early-stage life sciences fund investing in next-generation therapeutics, medical device, and diagnostics companies. Daniel leads Pathway’s operations and investment activities including the identification of new opportunities, diligence, and portfolio company support and has overseen recent investments supporting technologies including novel biomaterials, molecular diagnostics, first-in-class small molecule therapeutics, antibody-oligonucleotide conjugates, RNAi therapeutics, bispecific antibody therapeutics, live bacterial therapeutics, and novel drug delivery devices. A cancer researcher by training, Daniel holds an MPH and PhD from Yale University and received post-doctoral training at Baylor College of Medicine. He has authored or co-authored over 25 peer-reviewed scientific articles and book chapters in the fields of cancer epidemiology and genetics.